Pliant Therapeutics (PLRX) Invested Capital (2019 - 2026)

Pliant Therapeutics (PLRX) has 8 years of Invested Capital data on file, last reported at $165.2 million in Q1 2026.

• Invested Capital for Q1 2026 came in at $165.2 million, down 42.54% year-over-year; the trailing twelve-month figure through Mar 2026 was $165.2 million (down 42.54% YoY), and the FY2025 annual result was $181.2 million, down 45.79% from the prior year.
• Invested Capital fell to $165.2 million in Q1 2026 per PLRX's latest filing, from $181.2 million in the prior quarter.
• Over five years, Invested Capital peaked at $571.9 million in Q1 2023 and troughed at $157.7 million in Q2 2022.
• A 5-year average of $342.9 million and a median of $334.3 million in 2024 frame the typical range for Invested Capital.
• The sharpest annual moves came in 2023 and 2025: Invested Capital soared 244.45% in 2023, then tumbled 45.79% in 2025.
• A 5-year view of Invested Capital shows it stood at $323.3 million in 2022, then soared by 49.61% to $483.6 million in 2023, then slumped by 30.88% to $334.3 million in 2024, then plunged by 45.79% to $181.2 million in 2025, then slipped by 8.85% to $165.2 million in 2026.
• Business Quant data shows PLRX's Invested Capital at $165.2 million in Q1 2026, $181.2 million in Q4 2025, and $230.7 million in Q3 2025.